A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

Category Primary study
JournalBlood
Year 2019
This article has no abstract
Epistemonikos ID: 7cba627bf248b000118d5fa8092208af5f39d4fd
First added on: Feb 11, 2025